Factor XII deficiency and cardiopulmonary bypass.
Factor XII initiates the intrinsic coagulation cascade and may affect the fibrinolytic system. Routine coagulation tests used during cardiopulmonary bypass (CPB) are abnormal in factor-XII-deficient patients and are useless for monitoring anticoagulation in these patients. A factor-XII-deficient patient requiring CPB is described. The baseline celite activated clotting time (ACT) was greater than 1400 seconds and the thrombin time was 12.4 seconds (control, 11.9 seconds). Two units of plasma were given resulting in an ACT of 173 seconds. Following 300 units/kg of heparin and during CPB, the ACT ranged from 670-596 seconds with the thrombin time greater than 200 seconds. Plasma provides exogenous factor XII allowing an endpoint on the ACT test and may protect against possible postoperative hypofibrinolytic complications. A commercially available modified thrombin time may also be useful and provide an endpoint during high-dose heparinization.
Wallock
M
M
Department of Cardiovascular Surgery, Evanston Hospital, IL 60201, USA.
Arentzen
C
C
Perkins
J
J
D000368:Aged; D001780:Blood Coagulation Tests; D002315:Cardiopulmonary Bypass; D005175:Factor XII Deficiency / Q000188:drug therapy*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic
D006493:Heparin